Please assess the completion status of the following clinical trial:

Trial Title: A Study of Leuprolide to Treat Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Voluntarily sign an IRB-approved informed consent form and any required privacy statement/authorization form.~* Pre-trial serum testosterone level \>150 ng/dL.~* Histologically-confirmed prostatic adenocarcinoma in Jewett Clinical Stage A2, B, C or D and TNM\* classification cT1b-4, N: any, M: any.~  \*Tumor/Nodes/Metastases~* Subjects with a rising PSA following radical prostatectomy defined as an increase of 0.2 ng/mL from the previous test on two consecutive testings or rising PSA following prostate irradiation using Phoenix Definition of a rise of greater than or equal to 2.0 ng/mL above the nadir.~* Prostate cancer and general clinical status is sufficient to warrant at least 48 weeks of continuous androgen deprivation treatment, without concomitant antiandrogen treatment.~* Eastern Cooperative Oncology Group (ECOG) Performance status grades 0,1,or 2 at the time of pre-trial screening.~* Life expectancy of at least 18 months.~* Subjects with serum creatinine ≤1.9 mg/dL, bilirubin ≤2.0 mg/dL (unless Gilbert's syndrome with normal AST, ALT); AST and ALT ≤2.5 times the upper limit of normal.~Exclusion Criteria:~* Requires additional treatment including radical prostatectomy, radiotherapy or cryotherapy of local disease.~* Historical, clinical, or radiographic evidence of central nervous system metastases, including spinal cord metastasis.~* Clinical evidence of urinary tract obstruction.~* History of bilateral orchiectomy, adrenalectomy, or hypophysectomy.~* History of clinical hypogonadism.~* Current malignancy or history of malignancy except for prostate cancer or basal or squamous cell carcinoma of the skin.~* Clinical or laboratory evidence of any severe underlying disease state (excluding prostate cancer) that would place subjects in additional jeopardy by participating in this trial.~* Hypersensitivity to leuprolide, polylactic acid, or any excipient of the drug.~* Incomplete recovery from the effects of any major surgery.~* History of receiving of the following prostate cancer therapies within 8 weeks prior to the Screening Visit: chemotherapy, immunotherapy, antiandrogen, radiation therapy, cryotherapy, strontium, or biological response modifiers.~* History of prostatic surgery within 4 weeks prior to the Screening Visit.~* Received hormonal therapy, including GnRH analogs (less than or equal to 6 month depot administration), estrogen, Megace and phytotherapy, within 32 weeks prior to the Screening Visit and during the trial.~* Alternative medical therapies which have an estrogenic, androgenic, or antiandrogenic effect (including phyto-estrogens and phyto-androgens) within 12 weeks prior to the Screening Visit and during the trial.~* Requires the chronic use of systemic corticosteroids and anticonvulsants that may affect bone loss such as carbamazepine, phenobarbital, phenytoin, valproic acid or primidone.~* May require antiandrogen, immuno-, or surgical therapy for prostate cancer during the trial.~* History of alcoholism or consumes \>14 alcoholic beverages per week or illicit drug abuse within 12 months prior to screening.~* Received therapy with a GnRH analog (1 year implant) within 60 weeks prior to the Screening Visit.~* Received therapy with finasteride or ketoconazole within 1 week prior to the Screening Visit; dutasteride within 25 weeks prior to the Screening Visit.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Leuprolide acetate - Formulation A (Type: EXPERIMENTAL): Leuprolide acetate 45 mg, 6-month depot
- Leuprolide acetate - Formulation B (Type: EXPERIMENTAL): Leuprolide acetate, 45 mg, 6-month depot

Based on this trial design, predict the completion outcome and termination type (if applicable).